Free Trial
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

Arch Therapeutics logo
$0.41
0.00 (0.00%)
(As of 10/29/2024 ET)

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Key Stats

Today's Range
$0.41
$0.41
50-Day Range
$0.17
$0.75
52-Week Range
$0.17
$18.00
Volume
103 shs
Average Volume
5,934 shs
Market Capitalization
$1.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Arch Therapeutics, Inc. (ARTH)
See More Headlines

ARTH Stock Analysis - Frequently Asked Questions

Arch Therapeutics' stock was trading at $7.24 on January 1st, 2024. Since then, ARTH shares have decreased by 94.3% and is now trading at $0.4095.
View the best growth stocks for 2024 here
.

Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its quarterly earnings results on Monday, August, 19th. The biotechnology company reported ($1.44) earnings per share for the quarter. The biotechnology company earned $0.03 million during the quarter.

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), Adobe (ADBE), General Electric (GE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
8/19/2024
Today
10/30/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
$-6,980,000.00
Net Margins
-8,257.70%
Pretax Margin
-8,257.70%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($2.43) per share

Miscellaneous

Free Float
4,529,000
Market Cap
$1.94 million
Optionable
Not Optionable
Beta
3.59

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (OTCMKTS:ARTH) was last updated on 10/30/2024 by MarketBeat.com Staff
From Our Partners